Delivery Order SPE2DB20D3103-SPE2DB26FL4Q2
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,036.96 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on June 2, 2025, with completion scheduled for June 3, 2025. This non-competitive, firm fixed-price delivery order represents a continuation of pharmaceutical procurement through the DLA's medical supply chain. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical...
- The Defense Logistics Agency (DLA) awarded a $11,458.33 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on June 13, 2025, with an ultimate completion date of June 16, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor...
- The Defense Logistics Agency awarded a $64,924.28 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on October 30, 2025, with a completion date of October 31, 2025. This competitively awarded, firm fixed price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The company's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pen injections (2 ml quantity) with a ceiling value of $21,486.82. This is a firm fixed price delivery order issued under a non-competitive, non-set-aside procurement. The order is set for ultimate completion by September 11, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $34,724.93 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a $109,423.55 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on September 17, 2025, with an ultimate completion date of September 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,721.25 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on September 5, 2025, with a completion date of September 8, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under a larger indefinite delivery contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,906.97 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-set-aside, competitively awarded contract uses firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $21,278.76 to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999 and extending through December 2026. The delivery is scheduled for completion by October...
- The Defense Logistics Agency awarded a $16,998.05 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery is scheduled to occur at AmerisourceBergen's...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB26FL4Q2Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,744.50 to AmerisourceBergen Drug Corp on October 31, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This competitively awarded, firm fixed-price contract carries an ultimate completion date of November 3, 2025, and represents a non-set-aside procurement. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's comprehensive IDC vehicle enables delivery of a wide range of pharmaceutical products and medical supplies across multiple therapeutic domains to customers including the Defense Health Agency and U.S. Coast Guard. This delivery order for Dupixent, a specialty medication used primarily for treating eczema and asthma, exemplifies the company's role in supplying brand-name pharmaceutical products through the DLA's global pharmaceutical support network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.7k | 10/31/25 |